Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 29, 2009
[Current clinical trials using new targeted therapies for myeloid leukemia and the research trends]Jo Ishizawa, Hideyuki Saya
Experimental Hematology|June 22, 2016
Pharmacological activation of wild-type p53 in the therapy of leukemiaKensuke Kojima, Jo Ishizawa, Michael Andreeff
Cells|May 16, 2023
Molecular Mechanisms of Ferroptosis and Updates of Ferroptosis Studies in Cancers and LeukemiaHiroki Akiyama, Bing Z Carter, Michael Andreeff, et al.
Pharmacology & Therapeutics|June 7, 2015
Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) proteinJo Ishizawa, Kensuke Kojima, Numsen Hail, et al.
International Journal of Hematology|May 8, 2007
Quantification of circulating varicella-zoster virus DNA for follow-up in a case of visceral varicella-zoster infection ameliorated with intravenous acyclovirJo Ishizawa, Hiroyuki Fujita, Mai Iguchi, et al.
Biochemical and Biophysical Research Communications|December 5, 2012
The APC/C activator Cdh1 regulates the G2/M transition during differentiation of placental trophoblast stem cellsHideaki Naoe, Tatsuyuki Chiyoda, Jo Ishizawa, et al.
International Journal of Oncology|August 4, 2004
Inhibition of the ubiquitin-proteasome pathway activates stress kinases and induces apoptosis in renal cancer cellsJo Ishizawa, Shuichi Yoshida, Mototsugu Oya, et al.
Haematologica|May 19, 2018
Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trialWeiguo Zhang, Charlie Ly, Jo Ishizawa, et al.
International Journal of Hematology|September 6, 2012
Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: a feasibility study in Japanese populationTomoki Ueda, Rioko Iino, Kenji Yokoyama, et al.
Cancer Science|October 10, 2015
Preclinical activity of the novel B-cell-specific Moloney murine leukemia virus integration site 1 inhibitor PTC-209 in acute myeloid leukemia: Implications for leukemia therapyYuki Nishida, Aya Maeda, Dhruv Chachad, et al.
Pageof 4